Print

ZIOPHARM Oncology, Inc. (ZIOP.OB) Presents Systemic, DNA/Cell Plasmid Therapy Showing Long-Term Persistence and Anti-Tumor Effects at EORTC-National Cancer Institute-American Association for Cancer Research Meeting  
11/7/2012 9:20:36 AM

NEW YORK, Nov. 7, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today results from a preclinical study demonstrating the long-term persistence and anti-tumor effects of a new synthetic biology approach (DNA/cell plasmid) to controlled protein production in vivo. This embedded controlled bioreactor study was presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, taking place November 6-9 in Dublin, Ireland, and was conducted jointly by ZIOPHARM and Intrexon Corporation, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function, ZIOPHARM's exclusive channel partner for the development of DNA therapeutics.
//-->